Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20118
- Development stage
- Phase 2
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HS-20118 is an investigational small molecule drug being developed primarily for the treatment of moderate to severe plaque psoriasis. It is administered orally and is currently in Phase 1 clinical trials, where its safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) are being evaluated in both healthy volunteers and patients with plaque psoriasis. The precise mechanism of action for HS-20118 has not been disclosed or defined publicly as of June 2025. The drug is a new molecular entity classified under antipsoriatics. Development and sponsorship are led by Jiangsu Hansoh Pharmaceutical Co., Ltd., also known as Hansoh Pharma[1][4][5][6][8].
Beyond the preview
Go deeper on HS-20118.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20118.